Inhibition of CTHRC-1 by its specific monoclonal antibody attenuates cervical cancer cell metastasis

Abstract

Although combination of surgery and chemo-radiotherapy could cure 80–95% of patients with early cervical cancer, there is still no satisfactory therapeutic strategies for locally advanced and metastatic cervical cancer patients. Our previous study has already investigated that CTHRC-1 is highly expressed not only in the local tissue but also in circulating serum of patients with cervical cancer and played important function on metastasis of cervical cancer cells. In present study, we aimed to see whether circulating specific monoclonal antibody (mAb) to CTHRC-1could inhibit the metastasis of advanced cervical cancer. Therefore, we innovatively generated one specific and sensitive mAb against CTHRC1 and found the CTHRC1 mAb could attenuate the promoting function of rCTHRC-1 on wound healing and invasion of SiHa cell in vitro. In addition, administration of mAb on the lung metastasis mouse model of cervical cancer strongly inhibited the level of metastasis. Taken together, targeting on CTHRC-1 is greatly beneficial not only for diagnosis but also for treatment of cervical cancer, which providing experimental and theoretical basis for developing a novel precise treatment of cervical cancer and improving patient survival rate.

Keywords

• Cervical cancer
• CTHRC-1
• Monoclonal antibody drug